Effects of trabectedin injection: A Synthesis of Findings from 10 Studies

  1. Home
  2. Effects of trabectedin injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of trabectedin injection: A Synthesis of Findings from 10 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of trabectedin injection: A Synthesis of Findings from 10 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Trabectedin has shown promise in treating various cancers. 8 demonstrated that trabectedin administered intra-arterially significantly reduced tumor volume in a mouse model of cisplatin-resistant relapsed osteosarcoma. Another study, 5 , found trabectedin to inhibit both growth and metastasis in cutaneous melanoma. The research also showed that trabectedin reduces tumor blood vessel density and tumor-associated macrophages, suggesting a potential mechanism of action through targeting the tumor microenvironment. 4 explored the role of trabectedin in skeletal prostate cancer, demonstrating its ability to reduce tumor size and suppress M2 macrophages, which are known to promote tumor growth.

Benefits and risks

Benefit Summary

Trabectedin exhibits potential benefits for various cancers, including cisplatin-resistant relapsed osteosarcoma, cutaneous melanoma, and skeletal prostate cancer. Its mechanism of action may involve targeting both cancer cells and the tumor microenvironment, potentially leading to greater efficacy and a wider range of applications.

Risk Summary

Commonly reported side effects of trabectedin include nausea, vomiting, diarrhea, rash, and fatigue. 3 highlighted the risk of extravasation, which can cause tissue damage if trabectedin leaks from the vein during injection. Trabectedin might also affect heart function and increase the risk of infections.

Comparison of studies

Similarities

Several studies demonstrate the potential of trabectedin as an effective treatment for various cancers. The studies consistently suggest that trabectedin can reduce tumor growth and affect the tumor microenvironment, highlighting its potential in battling cancer.

Differences

The efficacy and side effects of trabectedin may vary depending on the type of cancer and the method of administration. 7 investigated the use of nanoparticles to encapsulate trabectedin, suggesting a potential approach to improve drug delivery and potentially reduce extravasation risks, which was identified as a concern in 3 . Further research is necessary to fully understand the potential benefits and risks associated with trabectedin in different contexts.

Consistency and contradictions

While studies show that trabectedin exhibits antitumor activity, there are inconsistencies regarding the extent of its efficacy and potential side effects. These inconsistencies might be due to differences in cancer types, treatment protocols, and individual patient responses. Additional research is necessary to fully understand these variations and refine trabectedin's use in clinical settings.

Implications for real life

The findings suggest that trabectedin may be a promising treatment option for various cancers. However, it is crucial to consult a physician before considering trabectedin treatment, as its use involves potential risks and side effects. Individualized treatment plans are crucial to optimize benefits and minimize potential harms.

Limitations of current research

Current research on trabectedin has some limitations. The exact mechanism of action is not fully understood, and the efficacy and side effects might vary based on several factors. Additionally, the studies primarily involve preclinical models, and further research with human subjects is needed to confirm the findings.

Future research directions

Future research should focus on elucidating the precise mechanisms of action of trabectedin, exploring different delivery methods to enhance its efficacy, and developing strategies to mitigate potential side effects. Clinical trials with human subjects are crucial to confirm its safety and efficacy in various cancer types and patient populations.

Conclusion

Trabectedin shows promise as a potential treatment for various cancers, but further research is essential to optimize its use and address potential limitations. If you are considering trabectedin treatment, consult a physician to discuss the benefits, risks, and potential side effects. Staying informed and discussing treatment options with your doctor is crucial for making informed decisions about your healthcare.

Literature analysis of 10 papers
Positive Content
10
Neutral Content
0
Negative Content
0
Article Type
1
0
0
0
10
1.

Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites.

Author: AbecasisR, GuevaraM, MiguezC, CobasS, TergR

Diuretic action
Natriuretic action
Long-term effects unknown

Torsemide is a new loop diuretic that has shown, in short-term studies, to induce a longer and higher diuretic and natriuretic action than frusemide. However, torsemide long-term effects and complications have not been sufficiently investigated. The aim was to compare the efficacy and safety of torsemide versus frusemide in cirrhotic patients with uncomplicated ascites.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models.

Author: AbateAndrea, TamburelloMariangela, RossiniElisa, BasnetRam Manohar, RibaudoGiovanni, GianoncelliAlessandra, HantelConstanze, CosentiniDeborah, LaganàMarta, GrisantiSalvatore, TiberioGuido Alberto Massimo, MemoMaurizio, BerrutiAlfredo, SigalaSandra

ACC treatment

Trabectedin, a marine-derived antitumor agent, was found to significantly reduce tumor growth and metastasis formation in preclinical models of adrenocortical carcinoma (ACC). These findings support further clinical evaluation of trabectedin for the treatment of ACC.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma.

Author: CarminatiLaura, PinessiDenise, BorsottiPatrizia, MinoliLucia, GiavazziRaffaella, D'IncalciMaurizio, BelottiDorina, TarabolettiGiulia

Melanoma treatment

Trabectedin is a new drug that inhibits the growth and spread of melanoma. It works by targeting both the cancer cells and the tumor microenvironment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model.

Author: CaneseRossella, PalombelliGianmauro, ChiricoMattea, SestiliPaola, BagnoliMarina, CanevariSilvana, MezzanzanicaDelia, PodoFranca, IorioEgidio

EOC treatment
Non-invasive imaging
Tumor growth reduction
Short-lived responses

Trabectedin, a marine-derived antitumor agent, shows promising results in reducing tumor growth and altering metabolism in a human epithelial ovarian cancer (EOC) model. The study identified significant changes in functional MRI and MRS signals, suggesting potential for non-invasive monitoring of trabectedin's effectiveness in EOC patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin.

Author: Capasso PalmieroUmberto, MorosiLavinia, BelloEzia, PonzoMarianna, FrapolliRoberta, MatteoCristina, FerrariMariella, ZucchettiMassimo, MinoliLucia, De MaglieMarcella, RomanelliPierpaolo, MorbidelliMassimo, D'IncalciMaurizio, MoscatelliDavide

Cancer treatment
Vascular toxicity

This study developed a novel approach for producing self-assembling biodegradable and biocompatible poly(caprolactone)-based nanoparticles (NPs) using a simple syringe-based method. The NPs were used to formulate trabectedin, a potent anticancer therapeutic, and demonstrated similar antitumor activity as the commercially available formulation Yondelis® but without the severe local vascular toxicity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

Author: IgarashiKentaro, KawaguchiKei, MurakamiTakashi, KiyunaTasuku, MiyakeKentaro, NelsonScott D, DrySarah M, LiYunfeng, YanagawaJane, RussellTara A, SinghArun S, YamamotoNorio, HayashiKatsuhiro, KimuraHiroaki, MiwaShinji, TsuchiyaHiroyuki, EilberFritz C, HoffmanRobert M

Osteosarcoma treatment

This study evaluated the efficacy of intra-arterial (i.a.) administration of Salmonella typhimurium A1-R in a patient-derived orthotopic xenograft (PDOX) model of osteosarcoma. i.a. administration of S. typhimurium A1-R was significantly more effective than intravenous administration or cisplatinum treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.

Author: MecoDaniela, ColomboTina, UbezioPaolo, ZucchettiMassimo, ZaffaroniMarco, RiccardiAnna, FairclothGlynn, JoseJimeno, D'IncalciMaurizio, RiccardiRiccardo

Activity against resistant tumors
Additive antitumor effect
None reported

The combination of ET-743 and doxorubicin demonstrates an additive effect against human sarcoma cells, suggesting a potential synergistic effect. The combination is particularly effective for tumors with low sensitivity to either drug alone. No pharmacokinetic interaction between the two drugs was observed in mice.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.

Author: ValotiG, NicolettiM I, PellegrinoA, JimenoJ, HendriksH, D'IncalciM, FairclothG, GiavazziR

Ovarian cancer treatment

Ecteinascidin (ET)-743, a marine natural product, showed antitumor activity against human ovarian carcinoma xenografts. It was highly active against some tumor models, suggesting potential for clinical use.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.